Company name | Market Cap | Quality rating | Intrinsic value | 1Y Return | Revenue | Free Cash Flow | Revenue growth | FCF margin | Gross margin | ROIC | Total Debt to Equity |
$218.2B | 7.1 | $179.7 42.3% undervalued | 14.6% | $42.0B | $6,351.0M | 4.6% | 15.1% | 55.6% | 25.3% | 31.4% | |
$144.9B | 6.8 | $36.6 63.1% overvalued | 47.6% | $16.7B | $2,438.0M | 17.6% | 14.6% | 67.0% | 8.0% | 50.7% | |
$142.2B | 6.5 | $302.5 19.5% overvalued | 7.1% | $22.6B | $3,487.0M | 10.2% | 15.4% | 62.8% | 10.4% | 65.9% | |
$118.8B | 6.4 | $116.4 26.3% undervalued | 14.0% | $33.2B | $5,467.0M | 2.7% | 16.5% | 62.9% | 7.4% | 53.6% | |
$41.5B | 6.1 | $54.4 22.6% overvalued | (24.2%) | $5,724.3M | $289.9M | (4.7%) | 5.1% | 78.4% | 21.6% | 7.0% | |
$28.0B | 7.3 | $39.7 43.9% overvalued | (47.5%) | $4,033.0M | $630.7M | 11.3% | 15.6% | 60.4% | 21.7% | 120.3% | |
$24.4B | 5.3 | $69.1 162.7% undervalued | 31.5% | €18.0B | €1,145.0M | (0.8%) | 6.4% | 43.1% | (4.2%) | 63.4% | |
$22.6B | 5.8 | $179.6 59.1% undervalued | (9.6%) | $7,678.6M | $1,132.4M | 3.8% | 14.7% | 66.0% | 6.3% | 43.0% | |
$22.4B | 6.4 | $196.3 14.0% overvalued | 0.3% | $5,398.4M | $751.4M | (0.2%) | 13.9% | 44.7% | 8.2% | 35.6% | |
$18.0B | 7.9 | $106.7 59.0% overvalued | 51.7% | $1,900.3M | $303.0M | 12.0% | 15.9% | 76.4% | 26.9% | 6.9% | |
$12.7B | 6.0 | $68.3 137.3% undervalued | 10.9% | $11.4B | $787.0M | 8.9% | 6.9% | 69.9% | 14.5% | 63.1% |
As of today, Abbott Laboratories has a stock rating of 7 (out of 10), which is considered Great.
As of today, Abbott Laboratories has a Great stock rating, which is 42.3% undervalued. According to Value Sense backtesting, stocks with similar profile tend to outperform the market by 12.8%.